Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Icagen, Pfizer Enter Research Pact With Yale | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Icagen, Pfizer Enter Research Pact With Yale

Icagen and Pfizer have entered into a collaboration with the Yale School of Medicine to investigate potential new pain compounds identified by Icagen and Pfizer in their existing collaboration.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Icagen and Pfizer have entered into a collaboration with the Yale School of Medicine to investigate potential new pain compounds identified by Icagen and Pfizer in their existing collaboration.

P. Kay Wagoner, Ph.D., chief executive officer of Icagen, said, “We are very pleased that Yale researchers Stephen Waxman, M.D. and Sulayman Dib-Hajj M.D. have agreed to work with us and our partner Pfizer in the study of Nav1.7 channels from inherited erythromelalgia (IEM) patients. Drs. Waxman and Dib-Hajj are among the world’s leading researchers in the role of sodium channels in pain. The studies we are jointly undertaking should help us better understand how modulating Nav1.7 channels in IEM patients may reduce the extreme pain experienced by these patients. This information may additionally assist our broader efforts to find novel sodium channel treatments for patients with various pain conditions.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters